York-based Aptamer Group plc, the developer of molecule binding techniques for use in medicine and cosmetics, said its cash runway is “generous” ahead of its annual general meeting on Friday. 

Adam Hargreaves, Non-Executive Chairman, said in a statement: he following statement: “Since the fundraising of £2.6 million in July this year, we have met our cost-base reduction targets, streamlined our scientific production capabilities, and executed our new commercial growth strategy to deliver optimised products of high quality to our growing customer base.”

“Our increased commercial traction has secured newly signed contracts, currently up to the value of £471,000, which will ensure that the Group’s cash runway remains generous, allowing any licensing opportunities to evolve and potentially crystalise over this extended period.”

The company said it is now working with the majority of the larger global pharmaceutical companies, including AstraZeneca and Unilever.